Our prior quantification of brain GLP-1R and GIPR levels across age and in a 6-OHDA rodent model of PD, as well as in the substantia nigra of human PD and an age-matched control, demonstrates the retention of these drug targets during disease and aging [42]. This evidence concerns the gene GIPR and Parkinson disease.